BHC Stock Gets Stronger EPS Forecast from Zacks Research

Bausch Health Cos Inc. (NYSE:BHC) – Equities researchers at Zacks Research raised their Q3 2028 EPS estimates for shares of Bausch Health Cos in a research note issued on Tuesday, September 22nd. Zacks Research analyst Team now forecasts that the company will post earnings per share of $0.82 for the quarter, up from their prior estimate of $0.81. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.35 per share.

Several other brokerages also recently commented on BHC. Wall Street Zen raised Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Weiss Ratings upgraded shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. Finally, Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Bausch Health Cos has a consensus rating of “Hold” and a consensus price target of $8.00.

Bausch Health Cos Stock Down 1.8%

Shares of NYSE:BHC opened at $5.72 on Friday. The business has a 50 day moving average price of $6.10 and a 200 day moving average price of $5.53. Bausch Health Cos has a twelve month low of $4.33 and a twelve month high of $8.00. The company has a market cap of $2.14 billion, a price-to-earnings ratio of -1.93 and a beta of 0.37.

Bausch Health Cos (NYSE:BHC) last released its earnings results on Wednesday, July 29th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.96 by $0.30. The firm had revenue of $2.83 billion during the quarter, compared to analyst estimates of $2.59 billion. Bausch Health Cos had a negative net margin of 10.12% and a negative return on equity of 561.95%.

Institutional Trading of Bausch Health Cos

Several institutional investors have recently made changes to their positions in BHC. Paulson & CO. Inc. bought a new position in shares of Bausch Health Cos during the 2nd quarter worth approximately $361,151,000. Royal Bank of Canada boosted its stake in shares of Bausch Health Cos by 24.9% in the 1st quarter. Royal Bank of Canada now owns 11,363,498 shares of the company’s stock valued at $61,362,000 after purchasing an additional 2,262,894 shares in the last quarter. MFN Partners Management LP bought a new stake in shares of Bausch Health Cos in the 2nd quarter worth about $29,580,000. Norges Bank bought a new stake in shares of Bausch Health Cos in the 4th quarter worth about $25,592,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Bausch Health Cos by 10.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,604,818 shares of the company’s stock worth $19,456,000 after purchasing an additional 350,823 shares in the last quarter. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Bausch Health Cos news, insider Aimee Lenar sold 36,827 shares of Bausch Health Cos stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total transaction of $258,893.81. Following the sale, the insider owned 334,853 shares in the company, valued at $2,354,016.59. The trade was a 9.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by company insiders.

Bausch Health Cos Company Profile

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, branded and generic pharmaceuticals, over-the-counter products and medical devices across a range of therapeutic areas.

Its business includes Salix Pharmaceuticals, which focuses on gastrointestinal treatments; Ortho Dermatologics, which develops prescription therapies for dermatological conditions; and Solta Medical, which provides energy-based medical and aesthetic devices.